Janux Therapeutics, Inc.
JANX
$29.69
$1.003.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.95% | -370.87% | 59.63% | -25.53% | -1.64% |
| Total Depreciation and Amortization | 0.39% | 0.79% | -4.89% | 0.19% | 6.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -73.38% | 348.60% | -27.46% | 58.46% | -0.74% |
| Change in Net Operating Assets | -102.69% | 274.50% | -65.32% | -305.75% | 64.43% |
| Cash from Operations | -649.66% | 77.74% | 32.46% | -49.85% | 15.44% |
| Capital Expenditure | -68.00% | 73.68% | 51.78% | 61.75% | -9.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 167.49% | 106.66% | -68.04% | -1,075.59% | 119.08% |
| Cash from Investing | 167.68% | 106.64% | -67.83% | -1,122.53% | 118.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23,347.54% | -40.36% | -99.14% | 38,669.07% | -98.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23,347.54% | -40.36% | -99.14% | 38,669.07% | -98.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,239.82% | 106.10% | -202.35% | 9,330.00% | 112.40% |